Abstract

ObjectiveTo assess the reliability of ADC measurements in vitro and in cervical lymph nodes of healthy volunteers.MethodsWe used a GE 1.5 T MRI scanner and a first ice-water phantom according to recommendations released by the Quantitative Imaging Biomarker Alliance (QIBA) for assessing ADC against reference values. We analysed the target size effect by using a second phantom made of six inserted spheres with diameters ranging from 10 to 37 mm. Thirteen healthy volunteers were also scanned to assess the inter- and intra-observer reproducibility of volumetric ADC measurements of cervical lymph nodes.ResultsOn the ice-water phantom, the error in ADC measurements was less than 4.3 %. The spatial bias due to the non-linearity of gradient fields was found to be 24 % at 8 cm from the isocentre. ADC measure reliability decreased when addressing small targets due to partial volume effects (up to 12.8 %). The mean ADC value of cervical lymph nodes was 0.87.10-3 ± 0.12.10-3 mm2/s with a good intra-observer reliability. Inter-observer reproducibility featured a bias of -5.5 % due to segmentation issues.ConclusionADC is a potentially important imaging biomarker in oncology; however, variability issues preclude its broader adoption. Reliable use of ADC requires technical advances and systematic quality control.Key Points• ADC is a promising quantitative imaging biomarker.• ADC has a fair inter-reader variability and good intra-reader variability.• Partial volume effect, post-processing software and non-linearity of scanners are limiting factors.• No threshold values for detecting cervical lymph node malignancy can be drawn.

Highlights

  • Recent advances in medical imaging technology and drug therapeutics have accelerated the emergence of new quantitative imaging biomarkers (QIB) [1, 2]

  • The Apparent diffusion coefficient (ADC) reference value was measured at the image center using formula C

  • We found that signal-to-noise ratio (SNR) computed from diffusion scans at b = 0 was 17 1, lower than the recommended limit value (50 1)

Read more

Summary

Introduction

Recent advances in medical imaging technology and drug therapeutics have accelerated the emergence of new quantitative imaging biomarkers (QIB) [1, 2]. The multiplication of these QIBs is not always accompanied by. Eur Radiol (2018) 28:3362–3371 stringent validations establishing that QIBs are well designed to characterize a disease and its changes with therapy. This lack of validation creates a situation where QIBs are routinely used but with limited knowledge of their performances, precluding a larger adoption in clinical trials. Several studies have documented the incremental value of ADC assessment as a complement or substitute to standard sequences for the detection of malignant tumours [3], the degree of malignancy [4, 5] or to evaluate response to treatment [6,7,8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call